Saetersmoen, Michelle L.
Hammer, Quirin
Valamehr, Bahram
Kaufman, Dan S.
Malmberg, Karl-Johan
Funding for this research was provided by:
Cancerfonden
Article History
Received: 10 September 2018
Accepted: 28 September 2018
First Online: 25 October 2018
Compliance with ethical standards
:
: K.J. Malmberg and D.S. Kaufman serve on the Scientific Advisory Board of Fate Therapeutics and obtain research support. Bahram Valamehr is employed by Fate Therapeutics. The respective relationships have been reviewed and managed by University of San Diego California, Oslo University Hospital, and Karolinska Institutet in accordance with the institutions’ conflict of interest policies.